Sector News

Implant maker ChoiceSpine acquired by Altus Capital Partners

November 23, 2018
Life sciences

Specialized implant manufacturer ChoiceSpine was acquired by Altus Capital Partners, marking the firm’s second medtech acquisition in two years. Financial terms were not disclosed.

Based in Knoxville, Tennessee, and founded in 2006, ChoiceSpine works with physicians to develop minimally invasive products incorporating customized patient solutions, including cervical, thoracolumbar, interbody and lateral implants, as well as biologics kits.

“ChoiceSpine, a global medical device corporation specializing in innovative solutions for both spinal fusion hardware and biologics, demonstrates a track record of proven innovation, strong sales growth, increased distribution and the necessity of their products in the marketplace,” Altus co-founder and senior partner Gregory Greenberg said in a statement, which described how management will continue to invest in ChoiceSpine’s expansion.

“We look forward to working with Altus in further developing our offerings as well as expanding into new product verticals to continue to grow the company and provide patient solutions for the treatment of spinal disorders,” said ChoiceSpine co-founder Marty Altshuler.

Altus previously acquired MGC Diagnostics late last year, purchasing all outstanding shares of its common stock.

The St. Paul, Minnesota-based MGC develops, manufactures and markets noninvasive diagnostic kits aimed at heart and lung health, sold internationally through distributors and direct sales forces in the U.S., France and Belgium.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.